Skip to Main content Skip to Navigation
Journal articles

Initial dual oral combination therapy in pulmonary arterial hypertension

Abstract : Treatment for pulmonary arterial hypertension (PAH) has been underpinned by single-agent therapy to which concomitant drugs are added sequentially when pre-defined treatment goals are not met. This retrospective analysis of real-world clinical data in 97 patients with newly diagnosed PAH (86% in New York Heart Association functional class III−IV) explored initial dual oral combination treatment with bosentan plus sildenafil (n=61), bosentan plus tadalafil (n=17), ambrisentan plus tadalafil (n=11) or ambrisentan plus sildenafil (n=8). All regimens were associated with significant improvements in functional class, exercise capacity, dyspnoea and haemodynamic indices after 4 months of therapy. Over a median follow-up period of 30 months, 75 (82%) patients were still alive, 53 (71%) of whom received only dual oral combination therapy. Overall survival rates were 97%, 94% and 83% at 1, 2 and 3 years, respectively, and 96%, 94% and 84%, respectively, for the patients with idiopathic PAH, heritable PAH and anorexigen-induced PAH. Expected survival rates calculated from the French equation for the latter were 86%, 75% and 66% at 1, 2 and 3 years, respectively. Initial combination of oral PAH-targeted medications may offer clinical benefits, especially in PAH patients with severe haemodynamic impairment.
Complete list of metadata
Contributor : Laurent Jonchère <>
Submitted on : Saturday, March 28, 2020 - 3:55:22 PM
Last modification on : Monday, February 15, 2021 - 3:24:20 PM


2016 Sitbon et al., Initial du...
Files produced by the author(s)



Olivier Sitbon, Caroline Sattler, Laurent Bertoletti, Laurent Savale, Vincent Cottin, et al.. Initial dual oral combination therapy in pulmonary arterial hypertension. European Respiratory Journal, European Respiratory Society, 2016, 47 (6), pp.1727-1736. ⟨10.1183/13993003.02043-2015⟩. ⟨hal-01301539⟩



Record views


Files downloads